Immucell (ICCC) Accumulated Expenses (2010 - 2026)

Immucell (ICCC) has reported Accumulated Expenses for 15 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 28.86% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 28.86% YoY), and the FY2025 full-year result was $1.0 million, down 13.65% from the prior year.
• Accumulated Expenses improved to $1.4 million in Q2 2026 per ICCC's latest filing, from $1.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.4 million in Q2 2026 and bottomed at $250344.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $916622.4 across 5 years, with a median of $963765.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 244.78% in 2022, then slipped 17.21% in 2025.
• Over 5 years, Accumulated Expenses stood at $966553.0 in 2022, then slipped by 2.44% to $942999.0 in 2023, then gained by 26.8% to $1.2 million in 2024, then decreased by 13.65% to $1.0 million in 2025, then jumped by 31.52% to $1.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.4 million, $1.0 million, and $977466.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.